Abstract

Simple SummaryTumor angiogenesis and heterogeneity are associated with poor prognosis for breast cancer. Advances in computer technology have made it possible to noninvasively quantify tumor angiogenesis and heterogeneity appearing in imaging data. We investigated whether low-dose CT could be used as a method for functional oncology imaging to assess tumor heterogeneity and angiogenesis in breast cancer and to predict noninvasively histological biomarkers and molecular subtypes of breast cancer. Low-dose breast CT has advantages in terms of radiation safety and patient convenience. Our study produced promising results for the use of machine learning with low-dose breast CT to identify histological prognostic factors including hormone receptor and human epidermal growth factor receptor 2 status, grade, and molecular subtype in patients with invasive breast cancer. Machine learning that integrates texture and perfusion features of breast cancer with low-dose CT can provide valuable information for the realization of precision medicine.This prospective study enrolled 147 women with invasive breast cancer who underwent low-dose breast CT (80 kVp, 25 mAs, 1.01–1.38 mSv) before treatment. From each tumor, we extracted eight perfusion parameters using the maximum slope algorithm and 36 texture parameters using the filtered histogram technique. Relationships between CT parameters and histological factors were analyzed using five machine learning algorithms. Performance was compared using the area under the receiver-operating characteristic curve (AUC) with the DeLong test. The AUCs of the machine learning models increased when using both features instead of the perfusion or texture features alone. The random forest model that integrated texture and perfusion features was the best model for prediction (AUC = 0.76). In the integrated random forest model, the AUCs for predicting human epidermal growth factor receptor 2 positivity, estrogen receptor positivity, progesterone receptor positivity, ki67 positivity, high tumor grade, and molecular subtype were 0.86, 0.76, 0.69, 0.65, 0.75, and 0.79, respectively. Entropy of pre- and postcontrast images and perfusion, time to peak, and peak enhancement intensity of hot spots are the five most important CT parameters for prediction. In conclusion, machine learning using texture and perfusion characteristics of breast cancer with low-dose CT has potential value for predicting prognostic factors and risk stratification in breast cancer patients.

Highlights

  • Tumor angiogenesis and heterogeneity are associated with poor prognosis for breast cancer

  • We reviewed the clinical data to identify treatment failure, which was defined as locoregional recurrence, contralateral breast recurrence, or distant metastasis after treatment was complete, except in patients for whom distant metastasis or contralateral breast cancer had been recorded at the time of diagnosis [30]

  • The perfusion of hot spots and the time to peak (TTP) of hot spots were significantly associated with all histological factors including Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, Ki67 index, grade, and molecular subtype (p ≤ 0.04) (Figure S1)

Read more

Summary

Introduction

Tumor angiogenesis and heterogeneity are associated with poor prognosis for breast cancer. Hematogenous metastasis occurs once the connection between the tumor and systemic circulation is established and becomes persistent [2]. Heterogeneity has been observed between patients (intertumoral heterogeneity) and within each individual tumor (intratumoral heterogeneity) [3,4,5]. Intertumoral heterogeneity is classified according to histological biomarkers, such as hormone receptor or human epidermal growth factor receptor 2 (HER2) status, and is the basis for targeted therapy. Intratumoral heterogeneity reflects the diverse phenotypic cell populations, genetic instability, and tumor microenvironment. Assessment of tumor angiogenesis and heterogeneity in breast cancer is important for patient stratification for treatment and improving patient outcomes

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.